The disclosure relates to a Lactobacillus plantarum HG-23 and application thereof. The Lactobacillus plantarum HG-23 has been deposited with the China Center for Type Culture Collection as assigned Accession Number CCTCC No.: M2021330. The Lactobacillus plantarum HG-23 of the disclosure can be used for preparing hypolipidemic food or hypolipidemic drugs. The Lactobacillus plantarum HG-23 screened in the disclosure is good in safety, can tolerate gastric acid and bile salts, and survives and colonizes in intestinal tract to regulate and improve the intestinal microecological balance of a host, so as to play a beneficial effect and generate an exact healthy effect; in-vitro and animal tests show that the Lactobacillus plantarum HG-23 has a strong function of reducing triglyceride and cholesterol in blood.

Disclosed herein is an isolated strain of Lactobacillus acidophilus TW01, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33990. Also disclosed herein are use of the isolated strain of Lactobacillus acidophilus TW01 for alleviating an inflammation-related disorder and that for improving gut health.

The invention provides ingestible particles comprising a water-swellable or water-soluble polymeric component, a lipid component, and optionally an amino acid, a vitamin and/or a micro-nutrient. The polymeric component may be embedded in the lipid component. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The invention further provides methods for preparing the ingestible particles and uses thereof.

A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.

Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.

It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.

Contemplated compositions and methods are based on a combination of polyphenols commonly found in the Mediterranean diet that, when combined, reduce pro-inflammatory signaling and expression of senescence-associated genes and support mitochondrial biogenesis and cellular energy metabolism. Notably, the observed pleiotropic effects did not only span across multiple signaling pathways, but also exhibited synergistic activity with respect to a number of markers associated with reduction of age-related decline in energy, immunity, and increase or persistence of chronic subacute inflammation. Viewed from a different perspective, contemplated compositions represent a symphony of biochemically diverse molecules that form the foundation for numerous benefits typically observed with the Mediterranean diet.

The present invention is directed to a method for manufacturing an enzyme preparation, comprising at least one recombinant Actinoallomurus endopeptidase with glutenase activity, at high yields and suitable for human use. The invention is further directed to a recombinant expression vector for expressing the recombinant endopeptidase(s) of interest, and to a S. lividans host cell comprising said vector. Moreover, the present invention is directed the enzyme preparation obtained by said method, to formulations of the same and to clinical uses thereof.

A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.

Compositions are provided comprising a pro-reparative factor such as a colostrum, a nutritional protease inhibitor to decrease enzymatic digestion of the pro-reparative factors, and optionally a stabilizing agent, to allow the pro-reparative factors to reach the small intestine intact following oral administration. Methods are provided for treating, alleviating, and preventing inflammatory bowel disease (IBD) and other disorders of the gastrointestinal tract.